ARVN · Arvinas, Inc.
Market Cap
$615.61M
Shares
65.39M
ARVN metrics
69 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$9.39
Market cap
$615.61M
Price action
19 metricsPrice change (1W)
+2.3%
Price change (30D)
+8.2%
Price change (3M)
+26.5%
Price change (6M)
-31.0%
Price change (YTD)
-20.8%
Price change (1Y)
+23.4%
Trailing year
Price change (5Y)
-89.1%
52-week high
$13.83
52-week low
$6.98
Change from 52-week high
-32.1%
Change from 52-week low
+34.5%
Annualized volatility
54.5%
Beta
1.2
RSI (14D)
56.6
Price vs SMA 50
+8.3%
Price vs SMA 200
-10.9%
Avg volume (3M)
762,692
Relative volume
0.6
Average dollar volume
$6.41M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
65.39M
Valuation
12 metricsP / E (TTM)
39.1
Trailing earnings · reciprocal yield 2.6%
PEG ratio
—
EV / revenue
0.2×
reciprocal yield 656.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.9×
reciprocal yield 51.4%
P / book
1.1
reciprocal yield 91.3%
FCF yield
-33.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
1.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
4.1×
reciprocal yield 24.1%
EV / revenue historical average (5Y)
23.9×
reciprocal yield 4.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-04
Profitability
9 metricsGross margin
—
Operating margin
-5.7%
Trailing 12 months
Net margin
2.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$18.10M
Net income (TTM)
$9.30M
Trailing 12 months
Diluted EPS (TTM)
$0.24
FCF margin
-65.9%
Effective tax rate
7.0%
Growth
11 metricsRevenue growth YoY
+1,014.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$316.70M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-10.0%
Year over year · fewer shares
Revenue CAGR (3Y)
+26.0%
Revenue CAGR (5Y)
+58.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
1.7%
Return on assets
1.4%
Debt / equity
0.0
Current ratio
7.9
EBITDA (TTM)
−$15.20M
Free cash flow (TTM)
−$208.80M
Quick ratio
7.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$567.40M
Latest balance sheet
Cash & equivalents
$94.30M
Total assets
$675.10M
Total debt
$500,000
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$207.00M
Capital expenditures (TTM)
$1.80M
R&D (TTM)
$238.70M
SG&A (TTM)
—
Stock compensation (TTM)
$36.70M
R&D / revenue
75.4%
Stock compensation / revenue
11.6%
Ownership (13F)
3 metrics13F filers
202
13F filer change QoQ
-6
Institutional ownership
85.3%
Short interest
3 metricsShort interest
6.2%
Latest settlement · 3.3 days to cover
Days to cover
3.3d
Short-squeeze score
60 / 100
Insider activity
2 metricsNet insider buying (90D)
−$66,038
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1655759
CUSIP
04335A105
13F (30d)
166 filings
165 filers
Visit website
Investor relations